Spravato Treatment Explained

Spravato is a prescription medication that offers a novel approach to treating depression, particularly for those who have not found success with traditional antidepressants. It is the first FDA-approved nasal spray specifically for adults with TRD, a condition where individuals do not respond adequately to at least two different antidepressant therapies.

Unlike conventional antidepressants, which primarily target neurotransmitters like serotonin, norepinephrine, and dopamine, Spravato works on the brain’s glutamate system. Glutamate is a key neurotransmitter involved in synaptic plasticity—the ability of the brain’s synapses to strengthen or weaken over time, which is essential for learning, memory, and overall brain function. By modulating the glutamate system, Spravato can help restore neural connections that are disrupted in depression, leading to rapid and significant improvements in mood.

1. Initial Consultation:Before beginning treatment with Spravato, patients at Empire State Psychiatry undergo a thorough assessment by one of our experienced psychiatrists. This evaluation helps determine if Spravato is the appropriate treatment option based on the patient’s specific symptoms, medical history, and previous treatment experiences.
2. In-Office Administration: Spravato is administered in our office under the direct supervision of a healthcare professional. The treatment involves the patient self-administering the nasal spray while being closely monitored by our staff. This in-office administration is necessary because of the potential for side effects and the need for post-administration observation.
3. Post-Treatment Monitoring: After taking Spravato, patients remain in our office for at least two hours. During this time, we monitor for any adverse reactions and provide support to ensure the patient’s safety and comfort. This monitoring period is crucial as Spravato can cause side effects such as dizziness, nausea, increased blood pressure, and a feeling of dissociation (a sense of being detached from reality). 
4. Ongoing Treatment Plan: Spravato is usually administered twice a week for the first four weeks, followed by weekly or bi-weekly sessions, depending on the individual’s response to the treatment. Throughout this process, our psychiatrists regularly assess the patient’s progress and make any necessary adjustments to the treatment plan.

Spravato is specifically designed for adults with treatment-resistant depression who have not found relief from other antidepressant therapies. It is important to note that Spravato is used in conjunction with an oral antidepressant, not as a standalone treatment. Our team at Empire State Psychiatry carefully evaluates each patient to ensure that Spravato is the right fit for their treatment needs.